Trial Profile
A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Leflutrozole (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Mereo BioPharma
- 01 Sep 2023 Results assessing the efficacy and safety/tolerability of the aromatase inhibitor leflutrozole to normalise testosterone in Obesity-associated Hypogonadotropic Hypogonadism published in the European Journal of Endocrinology
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 15 Jan 2019 According to a Mereo BioPharma media release, abstract will be published online no later than 31 January 2019. It can be viewed after 31 January by searching for Mereo on the ENDO web program at https://www.abstractsonline.com/pp8/#!/5752.